文献速递美容整形颅颌面外科

围手术期雌激素激素治疗不增加面部女性化手术的静脉血栓栓塞风险

Perioperative Estrogen Hormonal Therapy Does Not Increase Venous Thromboembolism Risk in Facial Feminization Surgery.
PubMed 文献 · Plast Reconstr Surg · 2024-04-02

一项38年回顾性队列研究纳入953例面部女性化手术患者,评估继续激素治疗下的术后静脉血栓栓塞(VTE)发生率。1例(0.10%)发生VTE,与类似美容和正颌手术报道率相当;3个亚组间VTE发生率无显著差异(P > 0.99)。结论认为围手术期使用女性化激素治疗不增加VTE风险,因此继续用药是合理的。

要点

  • 面部女性化手术中继续激素治疗,术后VTE发生率为0.10%(1例)。
  • 3个激素管理亚组间VTE发生率无显著差异(P > 0.99)。
  • 作者认为围手术期继续女性化激素治疗是合理的。

核心结论

  • 围手术期使用女性化激素治疗不增加面部女性化手术患者的围手术期VTE风险。
  • 因此,作者认为继续这些药物直至手术期间是合理的。

研究设计与样本

  • 38年回顾性队列研究,来自2名外科医生(D.K.O.和J.C.D.-B.)的执业范围,评估继续激素治疗患者的术后VTE。
  • 1715例患者接受面部女性化手术,953例符合最终纳入标准。

主要发现

  • 1例患者(0.10%)术后诊断为VTE,与类似美容和正颌手术的报道文献率相当。
  • 所有患者平均Caprini评分为3.1 ± 1.0,平均手术时长为491.9 ± 111.0分钟。
  • 内部实践改变前后亚组分析:714例(77.7%)围手术期继续全剂量激素治疗,197例(20.7%)围手术期激素剂量减至25%至50%,8例未使用激素治疗或围手术期停止。
  • 3个亚组间VTE发生率无显著差异(P > 0.99)。

临床怎么用

  • 作者认为,在面部女性化手术患者中继续女性化激素治疗直至手术期间是合理的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Conflicting data exist regarding increased perioperative venous thromboembolism (VTE) risk with feminizing hormone therapy. The effect has been poorly studied within the transgender population. Acute perioperative cessation of feminizing hormone therapy often leads to unpleasant side effects and exacerbates gender dysphoria in the perioperative period. The authors sought to identify VTE incidence in patients undergoing facial feminization surgery while continuing hormone replacement therapy throughout the time of surgery. METHODS: A 38-year retrospective cohort study within a 2-surgeon practice (D.K.O. and J.C.D.-B.) was designed to evaluate postoperative VTE in patients continuing hormone therapy. The primary outcome variable was postoperative VTE. RESULTS: A total of 1715 patients underwent facial feminization surgery within our search window. A total of 953 patients met final inclusion criteria. One patient (0.10%) was diagnosed with a VTE postoperatively, comparable to reported literature rates for similar cosmetic and orthognathic procedures. The average Caprini score of all patients was 3.1 ± 1.0 and the average case length was 491.9 ± 111.0 minutes. Subgroup analysis of patients before and after internal practice changes identified 714 patients (77.7%) continuing full-dose hormonal therapy perioperatively, 197 (20.7%) undergoing hormonal dose reduction to 25% to 50% perioperatively, and 8 who were either not taking hormonal therapy or stopped in the perioperative period. There was no significant difference in VTE incidence among the 3 subgroups ( P > 0.99). CONCLUSIONS: Perioperative use of feminizing hormonal therapy does not increase risk for perioperative VTE in patients undergoing facial feminization surgery. Therefore, it is reasonable to continue these medications through the time of surgery. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Li AY, Park MJ, Fick J, et al. Perioperative Estrogen Hormonal Therapy Does Not Increase Venous Thromboembolism Risk in Facial Feminization Surgery. Plast Reconstr Surg. 2024. PMID: 38563527. doi:10.1097/PRS.0000000000011437

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。